{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T11:58:21Z","timestamp":1772366301422,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"M.C. and I.D. acknowledge the Fonds National de la Recherche Scientifique","award":["FNRS and T\u00e9l\u00e9vie 7.6508.20"],"award-info":[{"award-number":["FNRS and T\u00e9l\u00e9vie 7.6508.20"]}]},{"DOI":"10.13039\/100015400","name":"Fonds Erasme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>What is the risk of recurrence in young breast cancer survivors who undergo ARTs following completion of anticancer treatment?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>ART in breast cancer survivors does not appear to have a negative impact on disease-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>In healthy women, fertility treatment does not increase the risk of developing breast cancer. At the time of breast cancer diagnosis and before starting anticancer treatments, several studies have shown the safety of performing ART. However, the safety of ART in breast cancer survivors following completion of anticancer treatment remains under-investigated. In general, breast cancer survivors are counselled to avoid any hormonal treatment but there are limited data available on the effect of short exposure to high oestradiol levels during ART. The largest study in this regard included 25 breast cancer survivors exposed to ART and did not show a detrimental effect of ART on patient survival. Hence, taking into account that pregnancy after breast cancer does not affect cancer prognosis, defining the safety of ART in breast cancer survivors remains a priority.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>We conducted a retrospective multicentric matched cohort study including a cohort of breast cancer survivors who underwent ART (exposed patients) between January 2006 and December 2016. Exposed patients who were eligible for the study were matched according to known breast cancer prognostic factors. Matched breast cancer survivors did not undergo ART (non-exposed patients) and were disease-free for a minimum time that was not less than the time elapsed between breast cancer diagnosis and first ART for the matched ART-exposed patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Data were retrieved from all survivors who had been diagnosed with breast cancer in eight participating centres at an age of \u226440\u2009years, without metastasis, ongoing pregnancy, pre-existing neoplasia or ovarian failure. ART included ovarian stimulation for IVF\/ICSI, clomiphene citrate treatment and hormone replacement therapy for embryo transfer. Data were collected from an oncological database for the selection of breast cancer patients in the non-exposed group. Exposed patients were matched (1:2) for germline BRCA status, tumour stage, anticancer treatment and age, whenever feasible. Matched groups were compared at baseline according to characteristics using conditional logistic regression. Kaplan\u2013Meier curves were constructed to compare time to recurrence between groups, with the time of ART as starting point that has been adjusted in the non-exposed group. The analyses were performed using Stata IC\/15.1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>A total of 39 breast cancer patients in the ART group were eligible for the analysis and were matched with 73 controls. There was no statistical difference between the two groups for the presence of BRCA mutation, tumour characteristics, use of (neo)adjuvant chemotherapy and of adjuvant endocrine therapy. Exposed patients were younger than non-exposed patients (mean age 31.8 vs 34.3\u2009years, respectively; P\u2009&amp;lt;\u20090.001). In the ART group, 89.7% were nulliparous at diagnosis compared to 46.6% of controls (P\u2009&amp;lt;\u20090.001). ART was performed at a mean age of 37.1\u2009years old, after a median time of 4.1\u2009years following breast cancer diagnosis (range: 1.5\u201312.5). Median anti-M\u00fcllerian hormone at the time of ART was 0.28\u2009ng\/ml (range: 0\u20134.4) and median serum oestradiol peak level was 696.5\u2009pg\/ml (range: 139.7\u20134130). Median follow-up time from first attempt of ART was 4.6\u2009years (range: 2.4\u201312.5) in the ART group. Adjusted follow-up time for the non-exposed group was 6.9\u2009years (range: 1.1\u201316.5\u2009years) (P\u2009=\u20090.004). In the ART group, 59% of patients had a pregnancy after breast cancer compared to 26% in the non-exposed patients (P\u2009=\u20090.001). Breast cancer relapsed in 7.7% versus 20.5% women in the ART and non-exposed groups, respectively (hazard ratio 0.46, 95% CI 0.13\u20131.62, P\u2009=\u20090.23). Median time to relapse was 1.3 (range: 0.3\u20132.7) years versus 4.5 (range: 0.4\u201311.1) years after ART and adjusted time in the ART and non-exposed groups, respectively (P\u2009=\u20090.14).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>Although this is the first and largest multicentric study addressing the impact of ART on breast cancer recurrence to provide data on oestrogen exposure, only a small number of patients could be included. This reflects the reluctance of breast cancer survivors and\/or oncologists to perform ART, and highlights the need for a prospective data registry to confirm the safety of this approach. This would offer the possibility for these patients, who are at a high risk of infertility, to fully benefit from ART.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Although recent studies have proven that pregnancy after breast cancer has no detrimental impact on prognosis, counselling patients about the safety of ART remains challenging. Our study provides reassuring data on the use of ART in breast cancer survivors with favourable prognostic factors, for when natural conception fails.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>M.C. and I.D. are funded by FNRS, T\u00e9l\u00e9vie-FNRS and Fonds Erasme. M.D.V. is a CooperSurgical scientific advisory board member and receives lecture fees for MSD, Gedeon-Richter and Ferring, outside the submitted work. M.L. has acted as a consultant for Roche and Novartis and has received honoraria from Theramex, Roche, Lilly, Pfizer, Novartis and Takeda, outside the submitted work. I.D. has acted as a consultant for ROCHE and has received speaker\u2019s fees from Novartis, outside the submitted work. E.d.A. has received honoraria and is a Roche\/GNE, Novartis, SeaGen and Zodiac scientific advisory board member, has received travel grants from Roche\/GNE and GSK\/Novartis, and has received research grants from Roche\/GNE, Astra-Zeneca, GSK\/Novartis and Servier, outside the submitted work. A.D. is a recipient of a research grant from Ferring Pharmaceuticals and receives lecture and\/or consultancy fees from Merck, Gedeon-Richter and Ferring Pharmaceuticals, outside the submitted work. The remaining authors have no conflicts of interest to declare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deaa319","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T20:12:17Z","timestamp":1604002337000},"page":"381-389","source":"Crossref","is-referenced-by-count":16,"title":["Impact of ARTs on oncological outcomes in young breast cancer survivors"],"prefix":"10.1093","volume":"36","author":[{"given":"M","family":"Condorelli","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Fertility Clinic, Brussels, Belgium"},{"name":"Research Laboratory on Human Reproduction, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"De Vos","sequence":"additional","affiliation":[{"name":"UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Lie Fong","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Leuven University Fertility Centre, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Autin","sequence":"additional","affiliation":[{"name":"D\u00e9partement de gyn\u00e9cologie-obst\u00e9trique, CHU Saint-Pierre, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Delvigne","sequence":"additional","affiliation":[{"name":"Clinique CHC MontL\u00e9gia, Centre de procr\u00e9ation m\u00e9dicalement assist\u00e9e, Li\u00e8ge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Vanden Meerschaut","sequence":"additional","affiliation":[{"name":"Department for Reproductive Medicine, University Hospital Ghent, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Wyns","sequence":"additional","affiliation":[{"name":"Gynaecology and Andrology Department, Cliniques universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Imbert","sequence":"additional","affiliation":[{"name":"CHIREC, Centre de Procr\u00e9ation M\u00e9dicalement Assist\u00e9e, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Cheruy","sequence":"additional","affiliation":[{"name":"Centre hospitalier de l'Ardenne, Gyn\u00e9cologie obst\u00e9trique, Libramont, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Bouziotis","sequence":"additional","affiliation":[{"name":"H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Service de la Recherche Biom\u00e9dicale, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Delbaere","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Fertility Clinic, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Research Laboratory on Human Reproduction, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"},{"name":"Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, U.O.C. Clinica di Oncologia Medica, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Demeestere","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Fertility Clinic, Brussels, Belgium"},{"name":"Research Laboratory on Human Reproduction, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"2021012505311038800_deaa319-B1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/jcem-38-6-1009","article-title":"Blood production and ovarian secretion rates of estradiol-17 beta and estrone in women throughout the menstrual cycle","volume":"38","author":"Baird","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"2021012505311038800_deaa319-B2","first-page":"753","article-title":"High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols","volume":"12","author":"Ben-Haroush","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"2021012505311038800_deaa319-B3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021012505311038800_deaa319-B4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3322\/caac.21585","article-title":"Adolescent and young adult oncology\u2014past, present, and future","volume":"69","author":"Close","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2021012505311038800_deaa319-B5","first-page":"1","article-title":"ART in Europe, 2015: results generated from European registries by ESHRE","volume":"1","author":"De Geyter","year":"2020","journal-title":"Human Reprod Open"},{"key":"2021012505311038800_deaa319-B6","author":"ESHRE Female Fertility Preservation Guideline Development Group","year":"2020"},{"key":"2021012505311038800_deaa319-B7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20\u201339 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021012505311038800_deaa319-B8","doi-asserted-by":"crossref","first-page":"e7695","DOI":"10.1371\/journal.pone.0007695","article-title":"Breast cancer in young women: poor survival despite intensive treatment","volume":"4","author":"Fredholm","year":"2009","journal-title":"PLoS One"},{"key":"2021012505311038800_deaa319-B9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-015-3328-0","article-title":"Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies","volume":"150","author":"Gennari","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2021012505311038800_deaa319-B10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.ejca.2015.05.007","article-title":"Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome","volume":"51","author":"Goldrat","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021012505311038800_deaa319-B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-016-3989-3","article-title":"The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis","volume":"2","author":"Hartman","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021012505311038800_deaa319-B12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnci\/djr541","article-title":"Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review","volume":"104","author":"Howard-Anderson","year":"2012","journal-title":"J Natl Cancer I"},{"key":"2021012505311038800_deaa319-B13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1210\/jc.2015-3878","article-title":"Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer","volume":"101","author":"Kim","year":"2016","journal-title":"J Clin Endocr Metab"},{"key":"2021012505311038800_deaa319-B14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/bmj.320.7233.474","article-title":"Factors influencing the effect of age on prognosis in breast cancer: population based study","volume":"320","author":"Kroman","year":"2000","journal-title":"BMJ"},{"key":"2021012505311038800_deaa319-B15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejca.2015.07.046","article-title":"Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?","volume":"54","author":"Lambertini","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021012505311038800_deaa319-B16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.breast.2018.08.099","article-title":"The BCY3\/BCC 2017 survey on physicians\u2019 knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients","volume":"42","author":"Lambertini","year":"2018","journal-title":"Breast"},{"key":"2021012505311038800_deaa319-B17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jnci\/djx206","article-title":"Long-term safety of pregnancy following breast cancer according to estrogen receptor status","volume":"110","author":"Lambertini","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2021012505311038800_deaa319-B18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cncr.32546","article-title":"Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation","volume":"126","author":"Letourneau","year":"2020","journal-title":"Cancer"},{"key":"2021012505311038800_deaa319-B19","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/humrep\/dex218","article-title":"Update on fertility preservation from the Barcelona International Society for Fertility Preservation\u2013ESHRE\u2013ASRM 2015 expert meeting: Indications, results and future perspectives","volume":"32","author":"Martinez","year":"2017","journal-title":"Human Reprod"},{"key":"2021012505311038800_deaa319-B20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.fertnstert.2014.05.017","article-title":"Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies","volume":"102","author":"Meirow","year":"2014","journal-title":"Fertil Steri"},{"key":"2021012505311038800_deaa319-B21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ijc.32346","article-title":"Use of fertility drugs in early-onset female cancer survivors-A Finnish register-based study on 8,929 survivors","volume":"146","author":"Melin","year":"2020","journal-title":"Int J Cancer"},{"key":"2021012505311038800_deaa319-B22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.fertnstert.2017.10.029","article-title":"Long-term outcomes in cancer patients who did or did not pursue fertility preservation","volume":"109","author":"Moravek","year":"2018","journal-title":"Fertil Steril"},{"key":"2021012505311038800_deaa319-B23","author":"OECD\u2014Social Policy Division\u2014Directorate of Employment, Labour and Social Affairs","year":"2019"},{"key":"2021012505311038800_deaa319-B24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/humrep\/deg045","article-title":"Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen","volume":"18","author":"Oktay","year":"2003","journal-title":"Human Reprod"},{"key":"2021012505311038800_deaa319-B25","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","article-title":"Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation","volume":"23","author":"Oktay","year":"2005","journal-title":"JCO"},{"key":"2021012505311038800_deaa319-B26","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"JCO"},{"key":"2021012505311038800_deaa319-B27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO\u2013ESMO 4th international consensus guidelines for breast cancer in young women (BCY4","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"key":"2021012505311038800_deaa319-B28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/annonc\/mdt199","article-title":"ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"2021012505311038800_deaa319-B29","first-page":"1617","article-title":"Fertility drugs and cancer: a guideline","volume":"7","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","journal-title":"Fertil Steril"},{"key":"2021012505311038800_deaa319-B30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10549-017-4555-3","article-title":"Safety of fertility preservation in breast cancer patients in a register-based matched cohort study","volume":"167","author":"Rodriguez-Wallberg","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2021012505311038800_deaa319-B31","first-page":"1","article-title":"No increased risk of relapse of breast cancer for women who give birth after assisted conception","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Human Reprod Open"},{"key":"2021012505311038800_deaa319-B32","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2017-01138","article-title":"Managing menopausal symptoms and associated clinical issues in breast cancer survivors","volume":"102","author":"Santen","year":"2017","journal-title":"J Clin Endocr Metab"},{"key":"2021012505311038800_deaa319-B33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/humupd\/dmt034","article-title":"IVF and breast cancer: a systematic review and meta-analysis","volume":"20","author":"Sergentanis","year":"2014","journal-title":"Human Reprod Update"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/2\/381\/36094521\/deaa319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/2\/381\/36094521\/deaa319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:01:23Z","timestamp":1611619283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/2\/381\/6025911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,8]]},"published-print":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaa319","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,12,8]]}}}